CLINICAL_TRIALS
trial_result
· 2007-12-12
Clinical Trial Update: Effects of Atomoxetine on Cognitive Function in Schizophrenia [Phase 2]
Summary
A Phase 2 trial evaluating atomoxetine for cognitive function in schizophrenia has completed. The update reports its effects on cognitive outcomes.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Yale University | Conditions: Schizophrenia, Cognition | Phase 2 | Status: COMPLETED